Our two test groups were both cognitively healthy as defined after detailed neuropsychiatric testing and were biochemically differentiated based on cutoff levels that are established in AD for CSF Aß42 and total tau biomarkers. This evidence concerns the gene MAPT and Alzheimer disease.